ALX Oncology Holdings (ALXO) Earnings Date & Reports

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

ALXO is expected to report earnings to rise 1.59% to -17 cents per share on August 06

ALX Oncology Holdings ALXO Stock Earnings Reports

Q2'26

Est.

$-0.17

Q1'26

Beat

by $0.02

Q4'25

Missed

by $0.07

Q3'25

Missed

by $0.04

Q2'25

Missed

by $0.06

The last earnings report on May 08 showed earnings per share of -17 cents, beating the estimate of -18 cents. With 543.74K shares outstanding, the current market capitalization sits at 222.03M.

View a ticker or compare two or three

Compare

ALXO

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for ALXO